Back to Search
Start Over
The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols
- Source :
- Journal of Psychiatry and Neuroscience. July, 2019, Vol. 44 Issue 4, p223, 14 p.
- Publication Year :
- 2019
-
Abstract
- Studies of clinical populations that combine MRI data generated at multiple sites are increasingly common. The Canadian Biomarker Integration Network in Depression (CAN-BIND; www.canbind.ca) is a national depression research program that includes multimodal neuroimaging collected at several sites across Canada. The purpose of the current paper is to provide detailed information on the imaging protocols used in a number of CAN-BIND studies. The CAN-BIND program implemented a series of platform-specific MRI protocols, including a suite of prescribed structural and functional MRI sequences supported by real-time monitoring for adherence and quality control. The imaging data are retained in an established informatics and databasing platform. Approximately 1300 participants are being recruited, including almost 1000 with depression. These include participants treated with antidepressant medications, transcranial magnetic stimulation, cognitive behavioural therapy and cognitive remediation therapy. Our ability to analyze the large number of imaging variables available may be limited by the sample size of the substudies. The CAN-BIND program includes a multimodal imaging database supported by extensive clinical, demographic, neuropsychological and biological data from people with major depression. It is a resource for Canadian investigators who are interested in understanding whether aspects of neuroimaging--alone or in combination with other variables--can predict the outcomes of various treatment modalities.<br />Introduction Treatment of major depressive disorder (MDD) is evidence-based, but treatment selection is not personalized to the features of an individual's illness. (1) The discovery of biomarkers --or predictors--of treatment [...]
- Subjects :
- Pfizer Canada Inc.
Depression (Mood disorder) -- Research
Quality control
Evidence-based medicine
Aripiprazole -- Research
Psychotherapy
Pharmaceutical industry
Escitalopram -- Research
Magnetic resonance imaging
Cognitive therapy
Major depressive disorder
Antidepressants
Behavioral medicine
Therapeutics
Behavior therapy
Cognitive-behavioral therapy
Quality control
Health
Psychology and mental health
University of Toronto
Subjects
Details
- Language :
- English
- ISSN :
- 11804882
- Volume :
- 44
- Issue :
- 4
- Database :
- Gale General OneFile
- Journal :
- Journal of Psychiatry and Neuroscience
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.593148510
- Full Text :
- https://doi.org/10.1503/jpn.180036